Articles from Caidya

Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific.

Caidya, a leading global, mid-sized CRO, today announced the appointment of Brandon Pallott as its new chief commercial officer (CCO). In this role, he will focus on implementing transformative commercial strategies to ensure the organization not only adapts to the evolving market landscape but also leads the industry forward. On the heels of Caidya’s recent investment of $165M from Rubicon Founders, the company is poised to continue and improve its ability to deliver exceptional outcomes for the sponsors and patients.

Caidya, a leading global mid-sized CRO, today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders, a U.S.-based healthcare investment firm focused on building and growing transformational companies.

MORRISVILLE, N.C., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Caidya, the multi-therapeutic clinical research organization (CRO) focused on delivery excellence and an elevated customer experience, announced today the appointment of Barbara Lopez Kunz to the Company’s Board of Directors, effective November 1, 2022.

SHANGHAI and MORRISVILLE, N.C., Oct. 03, 2022 (GLOBE NEWSWIRE) -- dMed |Clinipace, the established contract research organization serving global innovators such as biotechs, announced today that it is changing its corporate name to Caidya (KAY-dee-uh).